Drugs / CD38-SADA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05994157 | Apr → Oct 2025 | non-Hodgkin lymphoma | Y-mAbs Therapeutics | Terminated | No outcome recorded Stop: Enrollment |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-04-27 | Y-mAbs Therapeutics | Results Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting ymabs.com ↗
Importantly, the model’s estimated linear clearance of low molecular weight CD38-SADA monomers was 20-times faster than the CD38-SADA tetramers, providing additional evidence for their significantly reduced levels before delivery of the radioactive payload in the second infusion. |
| 2024-12-07 | Y-mAbs Therapeutics | Results Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting ymabs.com ↗
Data from this poster demonstrate anti-tumor efficacy of CD38-SADA when used with Lutetium 177 (Lu177)-DOTA in a two-step approach to pre-targeted radioimmunotherapy (“PRIT”). |
| 2023-11-13 | Y-mAbs Therapeutics | Regulatory Y-mAbs Reports Third Quarter 2023 Financial Results and Recent Corporate Developments ymabs.com ↗
Supported by a solid financial foundation, we have advanced our novel SADA radioimmunotherapy platform with the continued execution of our Phase 1 GD2-SADA trial and the recent Investigational New Drug (“IND”) clearance of our CD38-SADA program. |
| 2023-10-17 | Y-mAbs Therapeutics | Regulatory Y-mAbs Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for CD38-SADA ymabs.com ↗
Clearance of CD38-SADA IND marks the second clinical development program utilizing the Company’s novel SADA technology platform |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-04-27 | Y-mAbs Therapeutics | Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting ymabs.com ↗ |
| 2025-04-25 | Y-mAbs Therapeutics | Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma ymabs.com ↗ |
| 2024-12-07 | Y-mAbs Therapeutics | Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting ymabs.com ↗ |
| 2023-11-13 | Y-mAbs Therapeutics | Y-mAbs Reports Third Quarter 2023 Financial Results and Recent Corporate Developments ymabs.com ↗ |
| 2023-10-17 | Y-mAbs Therapeutics | Y-mAbs Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for CD38-SADA ymabs.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD38-SADA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05994157 ↗ |
| Route | Intravenous | “Both will be administered as an IV infusions.” NCT05994157 ↗ |